JP2009529497A5 - - Google Patents

Download PDF

Info

Publication number
JP2009529497A5
JP2009529497A5 JP2008556619A JP2008556619A JP2009529497A5 JP 2009529497 A5 JP2009529497 A5 JP 2009529497A5 JP 2008556619 A JP2008556619 A JP 2008556619A JP 2008556619 A JP2008556619 A JP 2008556619A JP 2009529497 A5 JP2009529497 A5 JP 2009529497A5
Authority
JP
Japan
Prior art keywords
monoclonal antibody
ligand
pharmaceutical composition
human
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008556619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529497A (ja
JP5247474B2 (ja
Filing date
Publication date
Priority claimed from US11/364,013 external-priority patent/US7947496B2/en
Application filed filed Critical
Publication of JP2009529497A publication Critical patent/JP2009529497A/ja
Publication of JP2009529497A5 publication Critical patent/JP2009529497A5/ja
Application granted granted Critical
Publication of JP5247474B2 publication Critical patent/JP5247474B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008556619A 2006-02-28 2007-02-23 Ｃｄ４４の表面発現を証明する細胞の細胞障害性媒介 Expired - Fee Related JP5247474B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/364,013 2006-02-28
US11/364,013 US7947496B2 (en) 1999-10-08 2006-02-28 Cytotoxicity mediation of cells evidencing surface expression of CD44
PCT/CA2007/000281 WO2007098575A1 (en) 2006-02-28 2007-02-23 Cytotoxicity mediation of cells evidencing surface expression of cd44

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013029374A Division JP2013165710A (ja) 2006-02-28 2013-02-18 Ｃｄ４４の表面発現を証明する細胞の細胞障害性媒介

Publications (3)

Publication Number Publication Date
JP2009529497A JP2009529497A (ja) 2009-08-20
JP2009529497A5 true JP2009529497A5 (cg-RX-API-DMAC7.html) 2012-07-12
JP5247474B2 JP5247474B2 (ja) 2013-07-24

Family

ID=38458603

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008556619A Expired - Fee Related JP5247474B2 (ja) 2006-02-28 2007-02-23 Ｃｄ４４の表面発現を証明する細胞の細胞障害性媒介
JP2013029374A Pending JP2013165710A (ja) 2006-02-28 2013-02-18 Ｃｄ４４の表面発現を証明する細胞の細胞障害性媒介

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013029374A Pending JP2013165710A (ja) 2006-02-28 2013-02-18 Ｃｄ４４の表面発現を証明する細胞の細胞障害性媒介

Country Status (15)

Country Link
US (3) US7947496B2 (cg-RX-API-DMAC7.html)
EP (2) EP2508536A1 (cg-RX-API-DMAC7.html)
JP (2) JP5247474B2 (cg-RX-API-DMAC7.html)
CN (2) CN101432307B (cg-RX-API-DMAC7.html)
AU (1) AU2007219656B2 (cg-RX-API-DMAC7.html)
CA (1) CA2643708A1 (cg-RX-API-DMAC7.html)
CY (1) CY1115212T1 (cg-RX-API-DMAC7.html)
DK (1) DK1989233T3 (cg-RX-API-DMAC7.html)
ES (1) ES2444408T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ570776A (cg-RX-API-DMAC7.html)
PL (1) PL1989233T3 (cg-RX-API-DMAC7.html)
PT (1) PT1989233E (cg-RX-API-DMAC7.html)
SI (1) SI1989233T1 (cg-RX-API-DMAC7.html)
TW (1) TW200731987A (cg-RX-API-DMAC7.html)
WO (1) WO2007098575A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20080124327A1 (en) * 1999-10-08 2008-05-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) * 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7419792B2 (en) * 1999-10-08 2008-09-02 Arius Research Inc. Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
CN101663049A (zh) * 2007-03-09 2010-03-03 霍夫曼-拉罗奇有限公司 证明cd44表面表达的细胞的细胞毒性介导
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
US8853149B2 (en) 2010-03-19 2014-10-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Integrin interaction inhibitors for the treatment of cancer
WO2012129335A2 (en) * 2011-03-21 2012-09-27 H. Lee Moffitt Cancer Center And Research Institute, Inc Hyd1 peptides for relapsed cancer
JP6077997B2 (ja) 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
US10011635B2 (en) 2013-09-27 2018-07-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
CN109402064B (zh) * 2018-11-05 2021-05-14 湖南省肿瘤医院 杂交瘤细胞株及其产生的单克隆抗体和应用
CN112569351B (zh) * 2020-12-16 2021-10-15 南通大学 Cd44抗体在制备治疗帕金森疾病的药物中的应用
CN114250200A (zh) * 2021-12-23 2022-03-29 蚌埠医学院 一种非小细胞肺癌脑转移和脊髓转移的动物模型构建方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US486158A (en) 1892-11-15 John cook
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
EP0266032A1 (en) 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
AU613590B2 (en) 1986-11-19 1991-08-08 Bristol-Myers Squibb Company Hybridomas producing monoclonal antibodies to new mucin epitopes
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5171665A (en) 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5980896A (en) * 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
DE4014510A1 (de) 1990-05-07 1991-11-14 Kernforschungsz Karlsruhe Variante cd44-oberflaechenproteine, diese kodierende c-dna-sequenzen, antikoerper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
DE69229254T2 (de) 1991-10-30 1999-09-23 Idemitsu Kosan Co. Ltd., Tokio/Tokyo Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
IL105008A0 (en) 1992-03-13 1993-07-08 Yeda Res & Dev Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis
EP0672130A1 (en) 1992-11-20 1995-09-20 Isis Innovation Limited Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors
US5879898A (en) * 1992-11-20 1999-03-09 Isis Innovation Limited Antibodies specific for peptide corresponding to CD44 exon 6, and use of these antibodies for diagnosis of tumors
ATE244888T1 (de) 1993-02-05 2003-07-15 Epigen Inc Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy
US5693322A (en) 1993-03-11 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Enhanced intercellular interaction by associational antibody molecules
WO1995000658A1 (en) 1993-06-18 1995-01-05 Sirpa Jalkanen COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6
EP0744958B1 (en) 1994-01-31 2003-06-25 Trustees Of Boston University Polyclonal antibody libraries
UA58482C2 (uk) 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
EP0764030B1 (en) 1994-06-24 2000-09-20 Vladimir P. Torchilin Composition containing autoantibodies for tumor therapy and prophylaxis
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano
AU6721696A (en) 1996-07-15 1998-03-06 Human Genome Sciences, Inc. Cd44-like protein
DK0826696T3 (da) * 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
DE19653607A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
DE19708713C2 (de) 1997-03-04 2002-11-28 Boehringer Ingelheim Int Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen
US5816468A (en) * 1997-06-24 1998-10-06 Testo Industries Corp. No-idle-striking structure for nailing machines
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6657048B2 (en) 1999-10-08 2003-12-02 Arius Research, Inc. Individualized anti-cancer antibodies
US7252821B2 (en) 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US20040001789A1 (en) 1999-10-08 2004-01-01 Young David S. F. Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
US7189397B2 (en) 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6180357B1 (en) 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
RU2003130645A (ru) 2001-04-03 2005-04-10 Мерк Патент ГмбХ (DE) Опухолевые маркеры карциномы почечных клеток
CZ20033476A3 (cs) 2001-05-18 2004-05-12 Boehringeráingelheimáinternationalágmbh Protilátky specifické pro CD@@v
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
EP1455819A1 (en) 2001-12-21 2004-09-15 Arius Research, Inc. Individualized anti-cancer antibodies
WO2004024750A2 (en) * 2002-09-13 2004-03-25 Dyax Corporation Cd44-binding ligands
US7399835B2 (en) * 2004-02-26 2008-07-15 Arius Research Inc. Cancerous disease modifying antibodies
US7319674B2 (en) 2003-07-24 2008-01-15 Cisco Technology, Inc. System and method for exchanging awareness information in a network environment
US7348413B2 (en) * 2004-02-26 2008-03-25 Arius Research Inc. Cancerous disease modifying antibodies

Similar Documents

Publication Publication Date Title
JP2009529497A5 (cg-RX-API-DMAC7.html)
TWI432452B (zh) 針對ｈｅｒ-３之抗體類及其用途
KR102389083B1 (ko) 항-cd47 항체 및 그 용도
RU2492185C2 (ru) Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование
Welt et al. Phase I study of anticolon cancer humanized antibody A33
CN110305212A (zh) 抗cd47抗体及其用途
JP2014524746A5 (cg-RX-API-DMAC7.html)
RU2009148600A (ru) Химерные и гуманизированные антитела к cd44, которые опосредствуют цитотоксичность в отношении раковых клеток
CA2633171A1 (en) Antibodies against tumor-associated antigenic target (tat) polypeptides
JP2009539380A5 (cg-RX-API-DMAC7.html)
JP2014531409A5 (cg-RX-API-DMAC7.html)
JP2015533788A5 (cg-RX-API-DMAC7.html)
RU2014118773A (ru) Антитела к родственной раково-эмбриональному антигену молекуле клеточной адгезии (сеасам)
EP2371863A1 (en) Humanized anti CXCR4 antibodies for the treatment of cancer
HUE030578T2 (en) Use of Human Leukemia Inhibitor Antibody (LIF) and Antibodies to LIF to Treat Diseases Related to Unwanted Cell Proliferation
RU2009104624A (ru) Антитела, модифицирующие раковые заболевания
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
JP2013531655A5 (cg-RX-API-DMAC7.html)
JP2017538439A5 (cg-RX-API-DMAC7.html)
JP2019520034A5 (cg-RX-API-DMAC7.html)
JP2015523852A5 (cg-RX-API-DMAC7.html)
JP2003523207A5 (cg-RX-API-DMAC7.html)
RU2009131840A (ru) Антитела, модифицирующие раковые заболевания
JP2014515600A5 (cg-RX-API-DMAC7.html)
KR102486507B1 (ko) 플렉틴-1 결합 항체 및 그의 용도